← Leaderboards
Kirk Essenmacher
Triursus Therapeutics Incorporated
$451,715
Attributed
$451,715
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $399.7K · FY2020–21$500K$375K$250K$125K$0
'20
'21
Funding mix
By agency
NIH$451,715 · 1
By mechanism
R44$451,715 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Acute Graft Versus Host Disease”
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$8,557,384
- Sumithira Vasu · Ohio State University$5,042,295
- Benjamin G Vincent · Univ Of North Carolina Chapel Hill$2,589,461
- Parvathi Ranganathan · Ohio State University$1,925,208
- Martin Devenport · Oncoimmune, Inc.$1,832,372
- Houda Alachkar · University Of Southern California$1,769,974
Research focus
Acute Graft Versus Host DiseaseAllogenicAdverse EffectsApoptosisAreaArhgef5 GeneAutomobile DrivingBaseBench To BedsideBindingBiological MarkersBlood Cell CountCapitalCaringCell BankCell Culture TechniquesCellsCell Surface ReceptorsClinical ResearchClinical TrialsCollaborationsCommercializationComparative EfficacyComplication
Grant awards (2)
TIM-1 blocking mAbs for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation patients$52,000
R44 · FY2021 · CA · contact PI
TIM-1 blocking mAbs for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation patients$399,715
R44 · FY2020 · CA · contact PI